洛伐他汀治疗对循环单核细胞中低密度脂蛋白受体活性以及血浆脂蛋白结构和组成的影响。

Effects of lovastatin therapy on LDL receptor activity in circulating monocytes and on structure and composition of plasma lipoproteins.

作者信息

Raveh D, Israeli A, Arnon R, Eisenberg S

机构信息

Department of Medicine B, Hadassah University Hospital, Jerusalem, Israel.

出版信息

Atherosclerosis. 1990 May;82(1-2):19-26. doi: 10.1016/0021-9150(90)90139-a.

DOI:10.1016/0021-9150(90)90139-a

PMID:2360916

Abstract

The effect of lovastatin therapy on LDL-receptor activity in fresh monocytes and on the structure and composition of lipoproteins was determined in 9 patients with familial hypercholesterolemia (FH) and 8 patients with non-familial hypercholesterolemia (NFH). Lovastatin reduced LDL-cholesterol levels by 34.8 and 47.5%, respectively, in the 2 groups of patients, and plasma apo B levels by 33.3 and 42.5%. LDL receptor activity in fresh monocytes increased by 53% and 86% respectively. HDL-cholesterol and plasma apo A-I levels increased only in the NFH group, by 10.2 and 7.1%. Lipoproteins were separated by centrifugation on a zonal rotor. Except for the intermediate density lipoprotein (IDL) fraction, no changes were observed in the structure and composition of the various lipoproteins. The investigations thus demonstrated that lovastatin therapy is associated with a measurable and significant increase of LDL-receptor activity in circulating monocytes that may contribute to the lipid lowering action of the drug.

摘要

在9例家族性高胆固醇血症（FH）患者和8例非家族性高胆固醇血症（NFH）患者中，测定了洛伐他汀治疗对新鲜单核细胞中低密度脂蛋白受体（LDL-receptor）活性以及脂蛋白结构和组成的影响。洛伐他汀使两组患者的低密度脂蛋白胆固醇水平分别降低了34.8%和47.5%，血浆载脂蛋白B水平分别降低了33.3%和42.5%。新鲜单核细胞中的LDL受体活性分别增加了53%和86%。高密度脂蛋白胆固醇和血浆载脂蛋白A-I水平仅在NFH组有所升高，分别升高了10.2%和7.1%。通过区带转子离心分离脂蛋白。除中密度脂蛋白（IDL）部分外，未观察到各种脂蛋白的结构和组成有变化。因此，这些研究表明，洛伐他汀治疗与循环单核细胞中LDL受体活性的可测量且显著增加有关，这可能有助于该药物的降脂作用。